<DOC>
	<DOCNO>NCT02983071</DOCNO>
	<brief_summary>This study investigate potential clinical benefit G1T38 oral therapy combination fulvestrant patient hormone receptor-positive , HER2-negative metastatic breast cancer . The study open-label design , consist 2 part : dose-finding portion ( Part 1 ) , expansion portion ( Part 2 ) . Both part include 3 study phase : Screening Phase , Treatment Phase , Survival Follow-up Phase . The Treatment Phase begin day first dose study treatment complete Post-Treatment Visit . Approximately , 102 patient enrol study .</brief_summary>
	<brief_title>G1T38 , CDK 4/6 Inhibitor , Combination With Fulvestrant Hormone Receptor-Positive , HER2-Negative Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Confirmed diagnosis HRpositive , HER2negative breast cancer , amenable curative therapy Pre perimenopausal woman enrol amenable treated goserelin Patients must satisfy 1 follow criterion prior therapy : Progressed treatment within 12 month completion adjuvant therapy aromatase inhibitor tamoxifen Progressed treatment within 2 month end prior aromatase inhibitor therapy advanced/metastatic breast cancer , prior endocrine therapy advanced/metastatic breast cancer Received ≤ 2 chemotherapy regimen ( Part 1 ) ≤ 1 chemotherapy regimen ( Part 2 ) advanced/metastatic disease For Part 1 , evaluable measurable disease ( bone disease eligible Part 1 ) For Part 2 , measurable disease define RECIST , Version 1.1 ECOG performance status 0 1 Adequate organ function For Part 1 , prior treatment fulvestrant For Part 2 , prior treatment CDK inhibitor fulvestrant Active uncontrolled/symptomatic CNS metastasis , carcinomatous meningitis , leptomeningeal disease Chemotherapy within 21 day first G1T38 dose Investigational drug within 28 day first G1T38 dose Concurrent radiotherapy , radiotherapy within 14 day first G1T38 dose , previous radiotherapy target lesion site , prior radiotherapy &gt; 25 % bone marrow Prior hematopoietic stem cell bone marrow transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>CDK 4/6 Inhibitor</keyword>
	<keyword>HER2-Negative</keyword>
	<keyword>HR-Positive</keyword>
	<keyword>HR+</keyword>
	<keyword>HER2-</keyword>
	<keyword>HER2 -ve</keyword>
	<keyword>HER2 +ve</keyword>
</DOC>